A comprehensive new review has raised significant doubts about the effectiveness of daily aspirin use in preventing colon cancer among people at average risk. The analysis indicates that any potential protective benefits of aspirin against bowel cancer may take more than ten years to manifest, and even then, the evidence supporting such benefits is considered weak by medical experts.
The study highlights a critical concern regarding the risks associated with daily aspirin consumption, particularly the increased chance of serious bleeding events, which can begin shortly after starting aspirin therapy, even at low doses. This immediate risk contrasts sharply with the delayed and uncertain protective effects against cancer, challenging the widespread practice of recommending aspirin as a preventive measure for colorectal cancer in the general population.
Medical professionals emphasize that decisions about aspirin use for cancer prevention must be carefully individualized. Factors such as a person’s specific health profile, risk factors, and potential for bleeding complications should be thoroughly evaluated rather than applying broad, automatic guidelines for aspirin use.
The review calls for more targeted research to clarify which subgroups, if any, might safely benefit from aspirin for cancer prevention, underscoring the importance of personalized medicine in this area. Health authorities may consider revising existing recommendations on aspirin use following the findings.
